Disclosed herein are methods of treating cognitive and behavioral impairment in Down syndrome and/or Alzheimers disease patients, Alzheimers disease, neurodegenerative disease, cancer, DYRK1A-mediated disorders and methods of modulating and inhibiting DYRK1-A comprising use of catechins.